Article Versions Notes

Taramasso L, Falletta A, Ricci E, Orofino G, Squillace N, Menzaghi B, De Socio GV, Molteni C, Pellicanò GF, Gulminetti R, et al. Trajectories of CD4⁺/CD8⁺ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study. Viruses. 2022; 14(11):2315. https://doi.org/10.3390/v14112315

Taramasso, Lucia, Antonio Falletta, Elena Ricci, Giancarlo Orofino, Nicola Squillace, Barbara Menzaghi, Giuseppe Vittorio De Socio, Chiara Molteni, Giovanni Francesco Pellicanò, Roberto Gulminetti, and et al. 2022. "Trajectories of CD4⁺/CD8⁺ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study" Viruses 14, no. 11: 2315. https://doi.org/10.3390/v14112315

Taramasso, L., Falletta, A., Ricci, E., Orofino, G., Squillace, N., Menzaghi, B., De Socio, G. V., Molteni, C., Pellicanò, G. F., Gulminetti, R., Madeddu, G., Sarchi, E., Vichi, F., Celesia, B. M., Bonfanti, P., & Di Biagio, A., on behalf of the CISAI Study Group. (2022). Trajectories of CD4⁺/CD8⁺ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study. Viruses, 14(11), 2315. https://doi.org/10.3390/v14112315